

# Introduction to AMVUTTRA® (vutrisiran)

Please join your colleagues for a discussion about AMVUTTRA, sponsored by Alnylam Pharmaceuticals.

## This program will

- Discuss a hypothetical patient case, including symptom presentation, diagnosis, and management goals
- Provide an overview of the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM)
- Review the mechanism of action for AMVUTTRA
- Review the clinical profile of AMVUTTRA for the treatment of ATTR-CM
- Review AMVUTTRA access and support

## Presenters

Elaine Perkins, PA-C

Millennium Cardiology

and Kelly, treated with AMVUTTRA

## Date & Time

Wednesday, May 13, 2026 6:00 PM EDT

## Location

Capital Prime

2324 Showtime Drive Lansing, MI

Dinner will be provided.

To comply with PhRMA Code guidance, alcohol is not provided at Alnylam programs.

## REGISTER NOW!

Sign up at: <https://alnylamevents.com/hcpevents?id=EM-05790> or call 1-833-223-2204

**For questions, please contact:**

**Linda Warra at [lwarra@alnylam.com](mailto:lwarra@alnylam.com) and/or (734) 652-9899**

This program is intended for US healthcare professionals only. Guests and spouses may not attend this program. Additionally, any meals offered in connection with this program may be reportable and publicly disclosed as required by the Physician Payments Sunshine Act and any applicable state laws. US healthcare professionals must provide their NPI and/or State License Number to register for the program. This is not an accredited education program, and no CME credits are offered. Presenters are consultants of Alnylam.

## Indication

AMVUTTRA® (vutrisiran) is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.

Please see Important Safety Information on the next page and the full [Prescribing Information](#).

## Important Safety Information

### Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

### Adverse Reactions

The most common adverse reactions ( $\geq 5\%$ ) were pain in extremity, arthralgia, dyspnea, and vitamin A decreased.

For additional information about AMVUTTRA, please see the full [Prescribing Information](#).

